Clinical Research Directory
Browse clinical research sites, groups, and studies.
Chinese Adults With Kidney Disease
Sponsor: ADARx Pharmaceuticals, Inc.
Summary
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex mebranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Official title: A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-07-23
Completion Date
2028-07-10
Last Updated
2026-04-13
Healthy Volunteers
No
Interventions
ADX-038
siRNA duplex oligonucleotide
Telitacicept
fusion protein